Osteoporosis, fracture risk, and prosthodontic implications

International Journal of Prosthodontics

Volumn 22, Issue 5, 2009, Pages 505-506

  Koka, Sreenivas ^a   Salinas, Thomas J ^a   Kennel, Kurt A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE DENSITY; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FRACTURE; HUMAN; JAW DISEASE; OSTEOPOROSIS; RISK ASSESSMENT; TOOTH IMPLANTATION;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DENTAL IMPLANTS; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; JAW DISEASES; OSTEONECROSIS; OSTEOPOROSIS; RISK ASSESSMENT;

EID: 77649206432     PISSN: 08932174     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Dawson-Hughes B, National Osteoporosis Foundation Guide C. A revised clinician’s guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 2008;93:2463-2465.
2. Kanis JA. Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007;18:1033-1046.
3. FRAX - WHO Fracture Risk Assessment Tool Web Version 2.0. www.shef.ac.uk/FRAX/index.htm. Accessed February 3, 2009.
4. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008;19:449-458.
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. JAMA 2002;288:321-333.
6. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005;165:2414-2419.
7. Payne JB, Reinhardt RA, Nummikoski P, Patil KD. Longitudinal alveolar bone loss in postmenopausal osteoporotic/osteopenic women. Osteoporos Int 1999;10:34-40.
8. Yoshihara A, Seida Y, Hanada N, Miyazaki H. A longitudinal study of the relationship between periodontal disease and bone mineral density in community-dwelling older adults. J Clin Periodontol 2004;31:680-684.
9. Jeffcoat M. The association between osteoporosis and oral bone loss. J Periodontol 2005;76(11 suppl):2125-2132.
10. Krall EA. Osteoporosis and the risk of tooth loss. Clin Calcium 2006;16:287-290.
11. Jeffcoat MK, Cizza G, Shih WJ, Genco R, Lombardi A. Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis. J Int Acad Periodontol 2007;9:70-76.
12. Dao TT, Anderson JD, Zarb GA. Is osteoporosis a risk factor for osseointegration of dental implants? Int J Oral Maxillofac Implants 1993;8:137-144.
13. August M, Chung K, Chang Y, Glowacki J. Influence of estrogen status on endosseous implant osseointegration. J Oral Maxillofac Surg 2001;59:1285-1289.
14. Moy PK, Medina D, Shetty V, Aghaloo TL. Dental implant failure rates and associated risk factors. Int J Oral Maxillofac Implants 2005;20:569-577.
15. Friberg B, Ekestubbe A, Mellström D, Sennerby L. Brånemark implants and osteoporosis: A clinical exploratory study. Clin Implant Dent Relat Res 2001;3:50-56.
16. Holahan CM, Koka S, Kennel KA, et al. Effect of osteoporotic status on the survival of titanium dental implants. Int J Oral Maxillofac Implants 2008;23:905-910.
17. Woo SB, Hellstein JW, Kalmar JR. Narrative (corrected) review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761.
18. Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 2009;115:1631-1637.
19. Cafro AM, Barbarano L, Nosari AM, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Definition and management of the risk related to zoledronic acid. Clin Lymphoma Myeloma 2008;8:111-116.
20. Montefusco V, Gay F, Spina F, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaws in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 2008;49:2156-2162.
21. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-423.
22. Felsenberg D, Hoffmeister B, Amling M. Bisphosphonat therapie assoziierte. Kiefernekrosen Deutsches Arzteblatt 2006;46:A3078-A3080.
23. Koka S, Clarke BL, Amin S, Gertz MA, Ruggiero SL. Oral bisphosphonate therapy and osteonecrosis of the jaw: What to tell the concerned patient. Int J Prosthodont 2007;20:115-122.
24. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-2410.